Scisco Genetics

Executive Summary

Scisco Genetics, founded in 2017 and based in San Diego, is a direct-to-consumer (DTC) genetic testing company that provides at-home DNA analysis kits for personalized health, wellness, and ancestry insights. The company aims to democratize access to genetic information, enabling individuals to understand their traits, predispositions, and heritage. Operating at the intersection of consumer wellness and proactive health management, Scisco Genetics leverages a DTC model to empower users with actionable data for lifestyle and healthcare decisions. The platform offers a range of reports, from ancestry composition to carrier status and wellness markers, positioning itself as a accessible tool for health-conscious consumers. Despite the competitive landscape dominated by players like 23andMe and AncestryDNA, Scisco Genetics differentiates through a focus on actionable health insights and a user-friendly experience. The company is privately held with no disclosed funding rounds, indicating a lean operational model. As consumer interest in genetic testing grows, particularly for proactive health management, Scisco Genetics is well-positioned to capture market share. However, challenges include regulatory scrutiny from the FDA regarding health claims, data privacy concerns, and the need for continuous innovation to retain users. The company's future depends on expanding its test offerings, securing strategic partnerships, and navigating regulatory pathways to enhance credibility and trust.

Upcoming Catalysts (preview)

• Q4 2026Launch of Expanded Wellness and Disease Risk Panel70% success
• Q2 2027FDA Authorization for Pharmacogenomics Reports40% success
• Q3 2026Partnership with Major Telehealth Platform55% success